Apogene is bringing genetic sequencing to routine clinical diagnostics. Our platform streamlines the clinical sequencing workflow from a labor-intensive, multi-day and expensive workflow into a push-button, single-shift, low-cost test. The result is not just a better assay workflow, but a larger market: enabling many more labs to run sequencing in-house, rather than limiting it to specialized clinical and research centers.
Today, genetic sequencing is clinically valuable but operationally inaccessible for most labs. The bottleneck is not the sequencer itself, but the up-front workflow: sample prep, library prep, and cleanup. These steps are manual, slow, and difficult to scale for diagnostic testing throughputs. As a result, sequencing remains concentrated in specialized, low-scale centers instead of reaching the much broader clinical markets that need it.
Apogene has demonstrated proof-of-concept across the core pre-sequencing workflow (sample prep, library prep, and cleanup). The platform has been substantially de-risked through $3.6M in NIH-supported development at UC San Diego, with internal modeling indicating a disruptive cost position relative to current complex genetic sequencing workflows. Apogene is also in active dialogue with the market leader in sequencing regarding strategic collaboration and financing.
